Lupus & antiphospholipid syndrome
Poor health-related quality of life despite Lupus Low Disease Activity State or Definitions of Remission in systemic lupus erythematosus (SLE) remission in patients with SLE: results from a clinical trial setting
Authors' conclusion
Despite LLDAS or DORIS remission, notable proportions of SLE patients report poor HRQoL
Study context
- Population
- Patients with SLE in phase III trials of belimumab
- Participants
- 2,406 patients4 phase III trials
- Comparison
- Lupus Low Disease Activity State (LLDAS) vs Remission vs Sustained LLDAS vs Sustained remission
- Primary endpoint
- Prevalence of poor HRQoL (SF-36 PCS/MCS and domain scores ≤ normative fifth percentile; FACIT-F <30; EQ-5D problems) in LLDAS, DORIS remission, sustained LLDAS or sustained remission
- Follow-up
- Week 52
Methodological detailspooled analysis, BLISS-52, BLISS-76, BLISS-SC, EMBRACE
- Pooled analysis
- BLISS-52, BLISS-76, BLISS-SC, EMBRACE
Primary result
As reported in the abstract
Poor SF-36 PCS
Further findings
Poor SF-36 MCS · week 52
Poor SF-36 physical functioning domain (highest frequencies) · week 52
- Range across groups
- 24.0%-26.3%
Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) scores <30 · week 52
- Range across groups
- 18.5%-26.2%
EQ-5D pain/discomfort problems (greatest frequencies among EQ-5D dimensions) · week 52
- Range across groups
- 27.9%-28.7%
Change in health-related quality of life (HRQoL) over 52 weeks among patients achieving treatment goals
- Significant improvements in all HRQoL outcomes; PCS scores remained below population norms
Original publication
Poor health-related quality of life despite Lupus Low Disease Activity State or Definitions of Remission in systemic lupus erythematosus (SLE) remission in patients with SLE: results from a clinical trial setting. RMD Open. Published 31 October 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →